Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
about
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacinA Rapid Molecular Test for Determining Yersinia pestis Susceptibility to Ciprofloxacin by the Quantification of Differentially Expressed Marker Genes.Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children.The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristicsAge of Bioterrorism: Are You Prepared? Review of Bioweapons and Their Clinical Presentation for Otolaryngologists.Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria.Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model.Reducing antibacterial development risk for GSK1322322 by exploring potential human dose regimens in nonclinical efficacy studies using immunocompetent rats.
P2860
Q26771850-E8C60D0D-B4F5-4911-B5AE-DE4B52F8682BQ35363899-05D5C273-CEAA-4E0C-89B1-2E14519BC2F6Q36913976-1636EA5E-D3F5-4C46-90D8-DE92153AFB84Q37335844-A6509674-BF06-4A8F-859B-AA900C4ACFF6Q37712989-5E835A02-FF49-4DA6-ABCD-E10274794087Q38206493-E67A293F-BB75-40C2-8CC1-A75ECF14DF3CQ39293585-D960EDD8-1AD0-4D7B-9575-F4B5BD74F70DQ39704722-09904059-1450-4858-BD77-50AC68C98380Q40093553-74009E5C-532F-4791-9FE5-17A1AD5EDB1F
P2860
Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Use of an in vitro pharmacodyn ...... vents emergence of resistance.
@ast
Use of an in vitro pharmacodyn ...... vents emergence of resistance.
@en
Use of an in vitro pharmacodyn ...... vents emergence of resistance.
@nl
type
label
Use of an in vitro pharmacodyn ...... vents emergence of resistance.
@ast
Use of an in vitro pharmacodyn ...... vents emergence of resistance.
@en
Use of an in vitro pharmacodyn ...... vents emergence of resistance.
@nl
prefLabel
Use of an in vitro pharmacodyn ...... vents emergence of resistance.
@ast
Use of an in vitro pharmacodyn ...... vents emergence of resistance.
@en
Use of an in vitro pharmacodyn ...... vents emergence of resistance.
@nl
P2093
P2860
P356
P1476
Use of an in vitro pharmacodyn ...... vents emergence of resistance.
@en
P2093
G L Drusano
M Kinzig-Schippers
P2860
P304
P356
10.1128/AAC.00818-10
P407
P577
2010-11-29T00:00:00Z